^
Association details:
| Biomarker: | EGFR wild-type |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) + Imjudo (tremelimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study
Published date:
11/03/2022
Excerpt:
Patients (n = 1,013) with EGFR/ALK wild-type mNSCLC were randomly assigned (1:1:1) to tremelimumab 75 mg plus durvalumab 1,500 mg and platinum-based chemotherapy...PFS (HR, 0.72; 95% CI, 0.60 to 0.86; P = .0003; median, 6.2 v 4.8 months) and OS (HR, 0.77; 95% CI, 0.65 to 0.92; P = .0030; median, 14.0 v 11.7 months; 24-month OS, 32.9% v 22.1%) were significantly improved with T + D + CT versus CT.
Secondary therapy:
Chemotherapy
DOI:
10.1200/JCO.22.00975
Trial ID:
Source:
Title:
Patient reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON
Published date:
03/23/2022
Excerpt:
Pts (n=1013) with EGFR/ALK wild-type mNSCLC were randomised (1:1:1)….Improvement rates in PROs, including prespecified symptoms/domains of interest, were greater for T + D + CT and D + CT vs CT alone....The addition of D (+/- T) to CT improved efficacy while delaying deterioration in health-related QoL in pts with mNSCLC. Pts in the T + D + CT and D + CT arms tended to have longer TTD and greater rates of improvement in global health status/QoL, functioning and symptoms vs pts in the CT arm.
Secondary therapy:
Chemotherapy
Trial ID:
